Indevus Pharmaceuticals, Inc. Provides Update On Two Clinical Programs; Company Completes Enrollment In Phase II Trial For Pagoclone And First Phase III Trial For SANCTURA XR(TM)

LEXINGTON, Mass.--(BUSINESS WIRE)--March 6, 2006--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today reported that enrollment has been completed in the Company’s Phase II trial for pagoclone, in development for stuttering, and the first of its two ongoing Phase III trials for SANCTURA XR. SANCTURA XR is the once daily formulation of SANCTURA(R), which is currently marketed for overactive bladder.